Finance

Beta
Lists
ESL:FRA
EssilorLuxottica SA
€170.70
-0.76%
(-1.30) 1D
Jun 3, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ESL...
Open
€170.25
High
€171.55
Low
€170.15
Mkt. cap
78.67B
Avg. vol.
1.19K
Volume
863.00
P/E ratio
34.26
52-wk high
€323.50
52-wk low
€163.20
EPS
€4.98
No. of employees
156K
Open
€170.25
High
€171.55
Low
€170.15
Mkt. cap
78.67B
Avg. vol.
1.19K
Volume
863.00
P/E ratio
34.26
52-wk high
€323.50
52-wk low
€163.20
EPS
€4.98
No. of employees
156K
News stories
From sources across the web
Profile
EssilorLuxottica SA is a Franco-Italian vertically integrated multinational holding company registered in Charenton-Le-Pont and headquartered in nearby Paris. It designs, produces and markets ophthalmic lenses, equipment and instruments, prescription glasses and sunglasses. It was founded on 1 October 2018 and its name is an amalgamation of the two major corporations which merged to create it; the French Essilor and the Italian Luxottica. The two companies have, since the merger, been restructured as subsidiaries of the new entity. Under the terms of the merger agreement, Essilor would purchase Luxottica, but Luxottica's leadership would be guaranteed prominent positions in the newly-formed corporation as well as some seats on its board of directors; Luxottica founder, Leonardo Del Vecchio, was notably designated chairman. The first few years of EssilorLuxottica post-merger were marred by disputes over leadership roles, but Del Vecchio was able to bring them to a satisfactory end. Essilor and Luxottica were respectively the world's leading manufacturers of ophthalmic lenses and of eyeglasses; upon the merger, EssilorLuxottica thus became a monopoly. Wikipedia
About EssilorLuxottica SA
CEOFrancesco Milleri
Employees156K
FoundedOct 1, 2018
Headquarters-
SectorMedical device
Websiteessilor.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
7.01B
7.01B
7.23B
7.23B
Cost of goods sold
2.66B
2.66B
3.08B
3.08B
Cost of revenue
2.66B
2.66B
3.08B
3.08B
Research and development expenses
163.00M
163.00M
169.00M
169.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.20B
3.20B
3.26B
3.26B
Operating expense
3.36B
3.36B
3.42B
3.42B
Total operating expenses
6.01B
6.01B
6.50B
6.50B
Operating income
999.00M
999.00M
737.50M
737.50M
Other non operating income
-8.50M
-8.50M
-9.50M
-9.50M
EBT including unusual items
958.00M
958.00M
639.50M
639.50M
EBT excluding unusual items
956.00M
956.00M
688.00M
688.00M
Income tax expense
231.50M
231.50M
144.50M
144.50M
Effective tax rate
24.16%
24.16%
22.60%
22.60%
Other operating expenses
-2.00M
-2.00M
-9.00M
-9.00M
Net income
693.50M
693.50M
464.00M
464.00M
Net profit margin
9.89%
9.89%
6.41%
6.41%
Earnings per share
-
-
-
-
Interest and investment income
23.00M
23.00M
25.00M
25.00M
Interest expense
-73.50M
-73.50M
-83.50M
-83.50M
Net interest expenses
-50.50M
-50.50M
-58.50M
-58.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.52B
1.52B
1.26B
1.26B
Gain or loss from assets sale
-1.00M
-1.00M
1.50M
1.50M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer